10 Results for "

histone deacetylation

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "histone deacetylation" in MCE Product Catalog:

Cat. No.: HY-N2126
CAS No.: 952068-57-4
Parishin E is a modulator of hexokinase 2, lactate dehydrogenase A, and silent information regulator 6 (sirtuin 6), and is also a component present in Gastrodia elata Blume . Parishin E reduces the expression of hexokinase 2 and lactate dehydrogenase A, thereby regulating the process of cellular glycolysis . Parishin E regulates the deacetylation mediated by silent information regulator 6 (Sirtuin 6), and inhibits histone 3 lactylation modifications at the H3K18la and H3K27la sites . Parishin E inhibits macrophage polarization . Parishin E alleviates LPS-induced inflammatory responses and suppresses the expression of pro-inflammatory cytokines . Parishin E exerts ameliorating effects on rheumatoid arthritis . Parishin E can be used in studies related to rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-16138
CAS No.: 936221-33-9
Synonyms: CG-200745
Target:  

HDAC MDM-2/p53 Apoptosis

Research Areas:  

Cancer

Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects .
loading...
    loading...
Cat. No.: HY-16138A
CAS No.: 3078712-42-9
Synonyms: CG-200745 formic
Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat formic induces apoptosis and has anti-tumour effects .
loading...
    loading...
Cat. No.: HY-175988
CAS No.: 2548725-57-9
Research Areas:  

Cancer

DNMT/HDAC-IN-2 (Compound Y7) is a DNMT and HDAC inhibitor with IC50 values for DNMT1, HDAC1, and HDAC6 of 365, 0.2, and 8.91 nM respectively. DNMT/HDAC-IN-2 inhibits the proliferation of breast cancer cells. DNMT/HDAC-IN-2 significantly reduces tumor growth in xenografts and transgenic breast cancer mouse models. DNMT/HDAC-IN-2 can be used for the study of breast cancer .
loading...
    loading...
Cat. No.: HY-P2178
CAS No.: 157618-75-2
Target:  

HDAC

Research Areas:  

Cancer

Dihydrochlamydocin analog-1 (compound 2) is a Chlamydocin (HY-115761) analogue that inhibits histone H4 peptide deacetylation with IC50 of 30 nM .
loading...
    loading...
Cat. No.: HY-178485
Research Areas:  

Cancer

SJY26 is a PI3K/HDAC dual-target inhibitor with IC50s of 0.59 nM (PI3Kα and PI3Kδ), 2.02 nM (PI3Kγ), 12.69 nM (PI3Kβ) and 114 nM (HDAC1). SJY26 exhibits potent broad-spectrum anti-proliferative activity, and is particularly sensitive to Jurkat and PC9R cells. SJY26 inhibited the migration of PC9R cells, arrested the cell cycle and induced cell apoptosis. SJY26 reduces AKT phosphorylation, and decreases histone H3 deacetylation (Ac-H3). SJY26 can be used for the studies of non-small cell lung cancer and leukemia .
loading...
    loading...
Cat. No.: HY-149283
CAS No.: 3029138-43-7
Target:  

JAK HDAC Apoptosis

Research Areas:  

Cancer

JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers .
loading...
    loading...
Cat. No.: HY-182061
Target:  

Sirtuin

Research Areas:  

Cancer

SIRT6 activator 3 (Compound 24) is a SIRT6 activator with an EC50 of 5 μM. SIRT6 activator 3 exhibits histone deacetylation activity. SIRT6 activator 3 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-181126
CAS No.: 1029737-28-7
G194-0712 is a selective histone deacetylase 5 (HDAC5) activator with an EC50 of 7.96 μM and a Kd of 2.53 μM. G194-0712 restores ACTN4-K417 deacetylation and nuclear import, and increases CSTA expression. G194-0712 accelerates wound closure in chronic wound models, reducing wound area and epithelial gap. G194-0712 can be used for the research of chronic skin wounds, such as diabetic wounds, ischemic wounds, radiation injury wounds .
loading...
    loading...
Cat. No.: HY-150119
CAS No.: 1312013-29-8
Target:  

Sirtuin

Research Areas:  

Endocrinology

2'/3'-O-Acetyl-ADP-ribose sodium is an inhibitor of cell division and oocyte maturation. 2'/3'-O-Acetyl-ADP-ribose sodium causes delay or arrest of oocyte maturation and blastomere division in embryos. 2'/3'-O-Acetyl-ADP-ribose sodium is produced by Sir2 family deacetylases during the coupling of histone/protein deacetylation with β-NAD+ cleavage. In neutral or weakly alkaline aqueous solutions, the direct enzymatic product forms of 2'/3'-O-Acetyl-ADP-ribose sodium, namely the 2'-O-acetyl form and the 3'-O-acetyl form, undergo intramolecular lactone exchange reaction and interconvert with each other .
loading...
    loading...